SS Innovations International Marks Big NASDAQ Milestone for India
In a historic moment for the Indian medtech industry, SS Innovations International, the maker of India’s homegrown SSI Mantra surgical robot, rang the Nasdaq opening bell in New York. The event marked a significant milestone for the company and a proud moment for India’s medical technology sector globally.
Led by Dr. Sudhir Srivastava, the CEO of SS Innovations International, the company has made tremendous strides in the field of robotic surgery. In a little over a decade, SS Innovations has completed over 4,000 robotic surgeries, making it one of the most successful and innovative medtech companies in India.
The SSI Mantra surgical robot, developed by SS Innovations, is a pioneering technology that enables surgeons to perform complex surgeries with precision and accuracy. The robot’s advanced features and capabilities have revolutionized the field of surgery, enabling doctors to perform procedures that were previously considered challenging or impossible.
The Nasdaq listing is a significant achievement for SS Innovations International, marking the company’s entry into the global capital markets. The event was attended by dignitaries from the medical fraternity, industry experts, and investors, who gathered to witness this historic moment.
“We are thrilled to mark this significant milestone in our journey,” said Dr. Sudhir Srivastava, CEO of SS Innovations International. “The SSI Mantra surgical robot has been a game-changer in the field of surgery, and we are committed to continuing to innovate and push the boundaries of what is possible.”
The company’s success is a testament to India’s growing reputation as a hub for medical innovation and technology. With its skilled workforce, favorable business environment, and significant government support, India is becoming an attractive destination for medtech companies looking to establish a presence in the region.
SS Innovations International’s expansion plans are also a significant indicator of the company’s growth potential. The company is set to expand its operations to Europe and the US, with plans to establish a strong presence in these markets. This will enable the company to tap into new markets and expand its customer base, further cementing its position as a leading player in the global medtech industry.
The company’s success is also a reflection of the growing demand for robotic surgery worldwide. With the increasing need for minimally invasive procedures, robotic surgery is becoming an attractive option for patients and surgeons alike. The SSI Mantra surgical robot has been designed to meet this growing demand, offering a range of benefits that include reduced recovery time, less scarring, and improved patient outcomes.
The Nasdaq listing is a significant milestone for SS Innovations International, marking the company’s entry into the global capital markets. The event was attended by dignitaries from the medical fraternity, industry experts, and investors, who gathered to witness this historic moment.
“We are thrilled to mark this significant milestone in our journey,” said Dr. Sudhir Srivastava, CEO of SS Innovations International. “The SSI Mantra surgical robot has been a game-changer in the field of surgery, and we are committed to continuing to innovate and push the boundaries of what is possible.”
The company’s plans for expansion are also a significant indicator of its growth potential. With its focus on innovation, quality, and customer satisfaction, SS Innovations International is well-positioned to achieve significant growth in the coming years.
In conclusion, SS Innovations International’s Nasdaq listing is a significant milestone for the company and a proud moment for India’s medical technology sector globally. The company’s innovative products, commitment to quality, and plans for expansion make it a player to watch in the global medtech industry.
Source: https://www.healthcareradius.in/compliance-and-accreditation/ss-innovations
